Heather Ann McSharry - 05 Aug 2022 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)

Role: Director
Signature: By: /s/Adam Guttmann, as attorney in fact For: Heather Ann McSharry
Issuer symbol: JAZZ
Transactions as of: 05 Aug 2022
Net transactions value: -$587,618
Form type: 4
Filing time: 09 Aug 2022, 18:24:17 UTC
Previous filing: 10 Aug 2021
Next filing: 15 Aug 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	JAZZ	Ordinary Shares	Award	$0	+2,561	+23%	$0.000000	13,726	05 Aug 2022	Direct	F1
transaction	JAZZ	Ordinary Shares	Sale	$179,590	-1,179	-8.6%	$152.32	12,547	08 Aug 2022	Direct	F2
transaction	JAZZ	Ordinary Shares	Options Exercise	$442,240	+8,000	+64%	$55.28	20,547	08 Aug 2022	Direct
transaction	JAZZ	Ordinary Shares	Sale	$850,268	-5,500	-27%	$154.59	15,047	08 Aug 2022	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	JAZZ	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-8,000	-100%	$0.000000^*	0	08 Aug 2022	Ordinary Shares	8,000	$55.28	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 28, 2023.
F2	Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
F3	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.48 to $154.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4	This option was granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Option Plan. Subject to the Reporting Person's continuous service and certain additional conditions, this option vested over three years from the Vesting Commencement Date, with 1/3 that vested on the first anniversary of the Vesting Commencement Date and the remainder vested in 24 equal monthly installments thereafter.